Free Trial
NASDAQ:DRRX

DURECT (DRRX) Stock Price, News & Analysis

DURECT logo
$1.32
-0.03 (-2.22%)
(As of 10/31/2024 ET)

About DURECT Stock (NASDAQ:DRRX)

Key Stats

Today's Range
$1.27
$1.37
50-Day Range
$1.22
$1.62
52-Week Range
$0.47
$3.14
Volume
41,594 shs
Average Volume
137,851 shs
Market Capitalization
$40.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00
Consensus Rating
Hold

Company Overview

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

DURECT Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
68th Percentile Overall Score

DRRX MarketRank™: 

DURECT scored higher than 68% of companies evaluated by MarketBeat, and ranked 372nd out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    DURECT has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    DURECT has only been the subject of 1 research reports in the past 90 days.

  • Read more about DURECT's stock forecast and price target.
  • Earnings Growth

    Earnings for DURECT are expected to decrease in the coming year, from ($0.78) to ($1.02) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of DURECT is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of DURECT is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    DURECT has a P/B Ratio of 2.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about DURECT's valuation and earnings.
  • Percentage of Shares Shorted

    3.30% of the float of DURECT has been sold short.
  • Short Interest Ratio / Days to Cover

    DURECT has a short interest ratio ("days to cover") of 16, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in DURECT has recently increased by 1.93%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    DURECT does not currently pay a dividend.

  • Dividend Growth

    DURECT does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.30% of the float of DURECT has been sold short.
  • Short Interest Ratio / Days to Cover

    DURECT has a short interest ratio ("days to cover") of 16, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in DURECT has recently increased by 1.93%, indicating that investor sentiment is decreasing.
  • News Sentiment

    DURECT has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for DURECT this week, compared to 1 article on an average week.
  • Search Interest

    2 people have searched for DRRX on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, DURECT insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.30% of the stock of DURECT is held by insiders.

  • Percentage Held by Institutions

    Only 28.03% of the stock of DURECT is held by institutions.

  • Read more about DURECT's insider trading history.
Receive DRRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter.

DRRX Stock News Headlines

StockNews.com Begins Coverage on DURECT (NASDAQ:DRRX)
24/7 Automated Profits in Crypto
What if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast world of passive crypto income, where you set up a dependable income stream that works for you, whether you're at your computer or living your life.
DRRX Apr 2025 2.000 put
DRRX Apr 2025 2.000 call
See More Headlines

DRRX Stock Analysis - Frequently Asked Questions

DURECT's stock was trading at $0.59 at the start of the year. Since then, DRRX stock has increased by 116.9% and is now trading at $1.28.
View the best growth stocks for 2024 here
.

DURECT Co. (NASDAQ:DRRX) posted its quarterly earnings data on Tuesday, August, 13th. The specialty pharmaceutical company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.05. The specialty pharmaceutical company earned $2.17 million during the quarter, compared to the consensus estimate of $2.49 million. DURECT had a negative trailing twelve-month return on equity of 261.43% and a negative net margin of 187.80%.

DURECT shares reverse split on the morning of Tuesday, December 6th 2022. The 1-10 reverse split was announced on Tuesday, December 6th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of DRRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that DURECT investors own include CymaBay Therapeutics (CBAY), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), General Electric (GE), Catalyst Pharmaceuticals (CPRX) and Pfizer (PFE).

Company Calendar

Last Earnings
8/13/2024
Today
10/31/2024
Next Earnings (Estimated)
11/11/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:DRRX
Employees
80
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.00
High Stock Price Target
$37.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+1,455.6%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-27,620,000.00
Net Margins
-187.80%
Pretax Margin
-187.84%

Debt

Sales & Book Value

Annual Sales
$8.41 million
Book Value
$0.50 per share

Miscellaneous

Free Float
30,046,000
Market Cap
$41.90 million
Optionable
Optionable
Beta
1.13
10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:DRRX) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners